BPMC - Blueprint Medicines Corp
IEX Last Trade
95.37
1.760 1.845%
Share volume: 307,148
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$93.61
1.76
1.88%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-01 | 2023-02-16 | 2023-05-04 | 2023-08-02 | 2023-10-26 | 2024-02-15 | 2024-05-02 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 1.458 B | 1.350 B | 1.220 B | 1.106 B | 1.105 B | 1.049 B | 1.038 B | 1.204 B | |
| Current Assets | 1.228 B | 1.047 B | 900.344 M | 811.335 M | 808.172 M | 808.393 M | 776.602 M | 903.544 M | |
| Inventories | 35.253 M | 29.697 M | 17.521 M | 17.016 M | 16.457 M | 21.223 M | 30.940 M | 14.789 M | |
| Other Current Assets | 33.532 M | 35.024 M | 29.359 M | 33.418 M | 37.477 M | 33.351 M | 37.714 M | 40.095 M | |
| Short Term Investments | 33.532 M | 35.024 M | 29.359 M | 33.418 M | 37.477 M | 33.351 M | 37.714 M | 40.095 M | |
| Total Receivables | 21.915 M | 36.938 M | 31.303 M | 38.267 M | 41.254 M | 43.178 M | 60.047 M | 85.058 M | |
| Current Cash | 1.137 B | 944.992 M | 822.161 M | 722.634 M | 712.984 M | 710.641 M | 647.901 M | 763.602 M | |
| Total Non-current Assets | 230.727 M | 303.251 M | 320.026 M | 295.110 M | 297.127 M | 240.857 M | 261.873 M | 300.016 M | |
| Property Plant Equipment | 33.454 M | 33.344 M | 33.741 M | 36.957 M | 40.619 M | 41.959 M | 41.947 M | 40.167 M | |
| Other Assets | 24.699 M | 21.589 M | 34.471 M | 32.551 M | 29.560 M | 30.650 M | 22.578 M | 47.687 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.458 B | 1.350 B | 1.220 B | 1.106 B | 1.105 B | 1.049 B | 1.038 B | 1.204 B | |
| Total liabilities | 818.085 M | 835.225 M | 806.072 M | 795.315 M | 902.688 M | 918.641 M | 727.788 M | 883.319 M | |
| Total current liabilities | 175.510 M | 183.234 M | 172.684 M | 169.028 M | 197.384 M | 214.923 M | 206.603 M | 243.803 M | |
| Accounts Payable | 4.233 M | 2.729 M | 10.563 M | 6.979 M | 6.963 M | 4.710 M | 4.926 M | 4.858 M | |
| Other liabilities | 424.020 M | 436.970 M | 421.318 M | 417.092 M | 413.111 M | 413.432 M | 233.491 M | 225.617 M | |
| Current long term debt | 15.290 M | 16.851 M | 17.382 M | 17.857 M | 30.221 M | 30.278 M | 30.180 M | 48.259 M | |
| Long term debt | 123.060 M | 122.232 M | 122.130 M | 122.146 M | 208.157 M | 208.535 M | 209.205 M | 338.655 M | |
| Other liabilities | 424.020 M | 436.970 M | 421.318 M | 417.092 M | 413.111 M | 413.432 M | 233.491 M | 225.617 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 640.307 M | 514.677 M | 414.298 M | 311.130 M | 202.611 M | 130.609 M | 310.687 M | 320.241 M | |
| Common stock | 59.758 M | 59.881 M | 60.126 M | 60.516 M | 60.688 M | 60.902 M | 61.580 M | 62.854 M | |
| Retained earnings | -1.674 B | -1.833 B | -1.963 B | -2.095 B | -2.229 B | -2.340 B | -2.251 B | -2.301 B |